1. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–29.
2. US National Library of Medicine. Genetics Home Reference: Cholangiocarcinoma. 2020;2020.
3. Pellino A, Loupakis F, Cadamuro M, et al. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol. 2018;3:40.
4. Incyte Corporation. PEMAZYRE™ (pemigatinib) tablets, for oral use: US prescribing information. 2020. http://www.fda.gov/. Accessed 28 Apr 2020.
5. Incyte Corporation. FDA approves Incyte’s Pemazyre™ (pemigatinib) as first targeted treatment for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma [media release]. 17 Apr 2020. http://www.incyte.com.